You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CXCR1/2 inhibitor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer AJCC v8 Trial in

Recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +3 more
  • Biopsy
  • +6 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 9, 2023

Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma Trial in Houston (CXCR1/2

Recruiting
  • Metastatic Colon Adenocarcinoma
  • +20 more
  • CXCR1/2 Inhibitor SX-682
  • Nivolumab
  • Houston, Texas
    M D Anderson Cancer Center
Aug 17, 2022

no Condition Trial in Gières (DF2755A)

Completed
  • no Condition
  • Gières, France
    Eurofins Optimed
Mar 16, 2021

Waldenstrom's Macroglobulinemia Trial in Boston (Ulocuplumab, Ibrutinib)

Active, not recruiting
  • Waldenstrom's Macroglobulinemia
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Jun 20, 2022

Metastatic Colorectal Cancer Trial (LB-100, Azenosertib)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • (no location specified)
Oct 31, 2023

Metastatic Microsatellite-stable Colorectal Cancer Trial (LB-100, Atezolizumab)

Not yet recruiting
  • Metastatic Microsatellite-stable Colorectal Cancer
  • (no location specified)
Sep 1, 2023

New-onset type1 Diabetes Trial in Worldwide (Ladarixin, Placebo)

Recruiting
  • New-onset type1 Diabetes
  • Birmingham, Alabama
  • +57 more
Nov 21, 2022

Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Radiotherapy, PD-1/PD-L1 inhibitor, Granulocyte-macrophage

Recruiting
  • Advanced Solid Tumor
  • Refractory Tumor
  • Radiotherapy
  • +4 more
  • Suzhou, China
    The Second Affiliated Hospital of SchoowUniversity
Sep 14, 2023

Severe Aplastic Anemia, Single Lineage Cytopenias, T-LGL, Hypoplastic MDS Trial run by the National Heart, Lung, and Blood

Not yet recruiting
  • Severe Aplastic Anemia
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 23, 2023

Gastrointestinal Tumor Trial in Hangzhou (Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T,

Completed
  • Gastrointestinal Tumor
  • Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T, Germany)
  • tislelizumab (BeiGene, China) combined with PD-1 inhibitor
  • Hangzhou, China
    Zhejiang Hospital
Sep 1, 2023

Breast Cancer, Ovarian Cancer, Pancreas Cancer Trial (TNG348, Olaparib)

Not yet recruiting
  • Breast Cancer
  • +7 more
  • (no location specified)
Sep 26, 2023

Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7 Trial in Houston

Active, not recruiting
  • Metastatic Melanoma
  • +2 more
  • Aldesleukin
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 18, 2022

Cicatricial Alopecia Trial in New York (PF-06700841, Placebo)

Recruiting
  • Cicatricial Alopecia
  • New York, New York
    Icahn School of Medicine at Mount Sinai
Aug 16, 2022

Advanced Solid Tumor Trial in Beijing (Inosine 0.2g orally 3 times/day, PD-1/PD-L1 inhibitor ,chemo/targeting)

Completed
  • Advanced Solid Tumor
  • Inosine 0.2g orally 3 times/day
  • PD-1/PD-L1 inhibitor ,chemotherapy/targeting
  • Beijing, Beijing, China
    Qin li
Mar 30, 2023

Cancer, Cancer Metastatic, BRAF V600E Trial in Indianapolis (Abemaciclib, LY3214996)

Recruiting
  • Cancer
  • +6 more
  • Indianapolis, Indiana
    Indiana University Hospital / IU Simon Cancer Center
Jan 12, 2023

Head Neck Cancer, Intratumoral Injection Trial in Chicago (RiMO-301)

Recruiting
  • Head Neck Cancer
  • Intratumoral Injection
  • Chicago, Illinois
    University of Illinois at Chicago
Apr 28, 2023

Acute Myeloid Leukemia (AML) Trial in Birmingham, San Francisco, New York (ZN-d5 ZN-c3, ZN-c3)

Recruiting
  • Acute Myeloid Leukemia (AML)
  • Birmingham, Alabama
  • +2 more
Jan 3, 2023

Development ofEORTC Immune Checkpoint Inhibitor-specific Quality

Recruiting
  • Cancer
  • +2 more
    • Paris, France
      Institut Curie
    Nov 2, 2022

    HLA-A2 Positive Cells Present, Refractory Melanoma Trial in Buffalo (Alpha-type-1 Polarized Dendritic Cells, Celecoxib, PD-1

    Recruiting
    • HLA-A2 Positive Cells Present
    • Refractory Melanoma
    • Alpha-type-1 Polarized Dendritic Cells
    • +5 more
    • Buffalo, New York
      Roswell Park Cancer Institute
    Dec 12, 2022

    Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Trial (Giredestrant, Fulvestrant, Abemaciclib)

    Not yet recruiting
    • Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
    • (no location specified)
    Sep 26, 2023

    Neurofibromatosis 1 (NF1), Plexiform Neurofibromas (PN) Trial run by the NCI (Selumetinib)

    Active, not recruiting
    • Neurofibromatosis 1 (NF1)
    • Plexiform Neurofibromas (PN)
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 31, 2023

    Metastatic Breast Cancer, Advanced Breast Cancer, HR-positive Breast Cancer Trial (OP-1250, Ribociclib, Alpelisib)

    Not yet recruiting
    • Metastatic Breast Cancer
    • +3 more
    • (no location specified)
    Aug 18, 2022

    Gut and Tumor Microbiome in Advanced ER-positive and

    Not yet recruiting
    • Breast Cancer
    • Melanoma
    • Observation
    • (no location specified)
    Nov 6, 2023

    NSCLC, Carcinoma Breast Trial in Suzhou (Vinorelbine, Radiotherapy, PD-1/PD-L1 inhibitor)

    Not yet recruiting
    • Carcinoma, Non-Small-Cell Lung
    • Carcinoma Breast
    • Suzhou, China
      Second Affiliated Hospital of Soochow University
    Oct 29, 2022

    Type 2 Diabetes Trial in Seoul (SGLT2 inhibitor)

    Not yet recruiting
    • Type 2 Diabetes Mellitus
    • SGLT2 inhibitor
    • Seoul, Seodaemun-gu, Korea, Republic of
      Severance Hospital
    Nov 17, 2023